Financhill
Buy
61

CLBT Quote, Financials, Valuation and Earnings

Last price:
$18.26
Seasonality move :
10.65%
Day range:
$18.30 - $18.78
52-week range:
$13.10 - $26.30
Dividend yield:
0%
P/E ratio:
60.18x
P/S ratio:
10.05x
P/B ratio:
11.02x
Volume:
598.3K
Avg. volume:
1.3M
1-year change:
-18.21%
Market cap:
$4.5B
Revenue:
$401.2M
EPS (TTM):
$0.31

Analysts' Opinion

  • Consensus Rating
    Cellebrite DI Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $24.71, Cellebrite DI Ltd. has an estimated upside of 34.24% from its current price of $18.41.
  • Price Target Downside
    According to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $18.41.

Fair Value

  • According to the consensus of 6 analysts, Cellebrite DI Ltd. has 34.24% upside to fair value with a price target of $24.71 per share.

CLBT vs. S&P 500

  • Over the past 5 trading days, Cellebrite DI Ltd. has underperformed the S&P 500 by -2.91% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Cellebrite DI Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Cellebrite DI Ltd. has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Cellebrite DI Ltd. reported revenues of $126M.

Earnings Growth

  • Cellebrite DI Ltd. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Cellebrite DI Ltd. reported earnings per share of $0.08.
Enterprise value:
4B
EV / Invested capital:
8.52x
Price / LTM sales:
10.05x
EV / EBIT:
62.80x
EV / Revenue:
8.77x
PEG ratio (5yr expected):
-0.55x
EV / Free cash flow:
28.73x
Price / Operating cash flow:
32.93x
Enterprise value / EBITDA:
53.80x
Gross Profit (TTM):
$382.8M
Return On Assets:
10.44%
Net Income Margin (TTM):
16.74%
Return On Equity:
20.59%
Return On Invested Capital:
19.76%
Operating Margin:
15.2%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $306.1M $385.2M $455.9M $106.9M $126M
Gross Profit $255.7M $325.3M $382.8M $91.4M $105.7M
Operating Income $28M $56.5M $63.6M $19.7M $19.2M
EBITDA $38M $66.9M $74.3M $22.3M $21.9M
Diluted EPS -$0.32 -$1.55 $0.31 -$0.99 $0.08
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $271.3M $262.5M $369M $494.9M $668.4M
Total Assets $315.1M $352.5M $476.9M $629.2M $834.3M
Current Liabilities $403.7M $189.8M $226.8M $272.9M $316.9M
Total Liabilities $445.1M $293M $439M $330.9M $386.6M
Total Equity -$130M $59.5M $37.9M $298.3M $447.7M
Total Debt -- -- $7.3M $7.8M $17.8M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $94M $110M $152.7M $41.7M $33.3M
Cash From Investing -$63.1M -$130.4M -$38.1M -$18.7M $63.8M
Cash From Financing $19.2M $18.5M $29.4M $5.5M $5.3M
Free Cash Flow $87.8M $98.8M $139.1M $39.8M $30M
CLBT
Sector
Market Cap
$4.5B
$52.2M
Price % of 52-Week High
70%
58.93%
Dividend Yield
0%
0%
Shareholder Yield
-0.69%
--
1-Year Price Total Return
-18.21%
-15.16%
Beta (5-Year)
--
0.666
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $18.72
200-day SMA
Buy
Level $17.27
Bollinger Bands (100)
Buy
Level 15.93 - 18.81
Chaikin Money Flow
Buy
Level 38M
20-day SMA
Buy
Level $18.34
Relative Strength Index (RSI14)
Buy
Level 52.09
ADX Line
Buy
Level 17.44
Williams %R
Neutral
Level -56.6474
50-day SMA
Buy
Level $17.73
MACD (12, 26)
Buy
Level 0.33
25-day Aroon Oscillator
Buy
Level 80
On Balance Volume
Neutral
Level 74.6M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (9.5718)
Sell
CA Score (Annual)
Level (-0.7157)
Buy
Beneish M-Score (Annual)
Level (-5.223)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.4689)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Its services include training and advisory, value realization, advanced services, and technical customer support. The firm also offers software solutions and analytic tools designed to accelerate digital investigations and address the growing complexity of handling crime and security challenges in the digital era. The company was founded on April 13, 1999 and is headquartered in Petach Tikva, Israel.

Stock Forecast FAQ

In the current month, CLBT has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLBT average analyst price target in the past 3 months is $24.71.

  • Where Will Cellebrite DI Ltd. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Cellebrite DI Ltd. share price will rise to $24.71 per share over the next 12 months.

  • What Do Analysts Say About Cellebrite DI Ltd.?

    Analysts are divided on their view about Cellebrite DI Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellebrite DI Ltd. is a Sell and believe this share price will drop from its current level to $23.00.

  • What Is Cellebrite DI Ltd.'s Price Target?

    The price target for Cellebrite DI Ltd. over the next 1-year time period is forecast to be $24.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CLBT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Cellebrite DI Ltd. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CLBT?

    You can purchase shares of Cellebrite DI Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellebrite DI Ltd. shares.

  • What Is The Cellebrite DI Ltd. Share Price Today?

    Cellebrite DI Ltd. was last trading at $18.26 per share. This represents the most recent stock quote for Cellebrite DI Ltd.. Yesterday, Cellebrite DI Ltd. closed at $18.41 per share.

  • How To Buy Cellebrite DI Ltd. Stock Online?

    In order to purchase Cellebrite DI Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 29

Galecto, Inc. [GLTO] is down 12.13% over the past day.

Sell
20
SMX alert for Dec 29

SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.

Sell
11
CDNAF alert for Dec 29

Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock